Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03197064 · ClinicalTrials.gov registry record · Phase 4
Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia
A Phase 4 study of Postoperative Nausea, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT03197064: Completed Phase 4 study of Postoperative Nausea, sponsored by Stanford University.
NCT03197064 is a Phase 4 study of Postoperative Nausea that has completed, run by Stanford University. The registered enrollment target is 11 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03197064, a Phase 4 study of Postoperative Nausea, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if intravenous fosaprepitant can interfere with nervous system monitoring signals in patients having surgery under general anesthesia. This medication has numerous effects on the sensory nerve transmission which can theoretically have effects on the ability to accurately measure somatosensory evoked potentials.
Primary Outcome
Neuromonitoring modality utilized during surgical procedures potentially affecting sensory component of central and peripheral nervous system. SEPs are the electrical signals generated by the nervous system in response to somatosensory stimuli - typically through electrical stimulation of the median nerve. SEPs are read on the skull with electroencephalography (EEG). SEPs was recorded using a 4-channel EEG system at baseline (predose) and regularly after study drug administration.
Conditions Studied
Interventions
- DRUG Fosaprepitant 150 mg
Study Locations (1)
California
- Stanford University Medical Center - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2020-01-31 |
| Phase | Phase 4 |
What the finished NCT03197064 record still lists
NCT03197064 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Postoperative Nausea appearing as the primary indexed condition, and to 1 intervention - of which Fosaprepitant 150 mg is the first listed.
NCT03197064 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03197064 about?
NCT03197064 is a clinical study titled "Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia". The purpose of this study is to determine if intravenous fosaprepitant can interfere with nervous system monitoring signals in patients having surgery under general anesthesia. This medication has numerous effects on the sensory nerve transmission which can theoretically have effects on the ability ...
What is the current status of trial NCT03197064?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2018-01-01. Estimated completion is 2020-01-31.
What conditions does trial NCT03197064 study?
This clinical trial studies the following conditions: Postoperative Nausea.
What interventions are being tested in trial NCT03197064?
The interventions under investigation include: Fosaprepitant 150 mg (DRUG).
Who is sponsoring clinical trial NCT03197064?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03197064 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postoperative Nausea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03197064's enrollment target sits among peer trials
11 1931st of 2000 higher than 61 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI